3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Investor Presentation (August 2025)
50 slides from 3b Blackbio Dx's investor presentation, Aug 14, 2025
Slide 1: Cover letter to BSI
(Formerly – Kilpest India Limited) Ref. No.P-66/2025-26/30 August 14, 2025 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochemi
Slide 2: Investor Presentation August 2025
Since 1972 Investor Presentation August, 2025
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by 3B BlackBio Dx Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Financial Highlights – Q1 2025-26
Financial Highlights – Q1 2025-26 2,223.46 1,943.40 1,586.35 1,435.73 1,264.45 1,129.76 14.76 13.19 Revenue from PBT PAT EPS Operations Q1 2024-25 Q1 2025-26 Consolidated Q1 2024-25 Q1 2025-26 Revenue from Operations 1,943.40 2,223.46 Profit Before tax 1,435.73 1,586.35 Profit After tax 1,129.76 1,2
Slide 5: Key Highlights – Agrochemicals Division
Key Highlights – Agrochemicals Division Main Thrust Area of R&D Development of novel formulations for agriculture and public health which are less harmful and cost effective. Performance monitoring of existing products/process. Improvement in existing products/process with a customer driven ap
Slide 6: Agrochemicals - Existing Products
Agrochemicals - Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 •
Slide 7: Selected as part of Select 200 Companies
3B BlackBio has been selected as a part of “Select 200 Companies” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist.
Slide 8: Highlights Molecular Diagnostics (MDx) Division
Highlights Molecular Diagnostics (MDx) Division Q1 2025-26
Slide 9: Overview – MDx Division
Overview – MDx Division Founded: 2011 | 14+ years in molecular diagnostics Core Focus: Design, Development & Manufacture of Molecular Diagnostic Kits: qPCR Assays (TRUPCR ®) Lateral Flow Assays (TRURAPID ®) NGS Assays (TRUNGS ®) Product Portfolio: 120+ Molecular Diagnostic Assays Develop
Slide 10: Overview – MDx Division
Overview – MDx Division Well Established PAN-India & Comprehensive Brand Global Presence Molecular Diagnostics Only company to have Product & customer support Well established molecular qPCR Assays, Lateral Flow access available to over 600 diagnostics (MDx) brand Tests and NGS assays labs / hospita
Slide 11: Vision, Mission & Values
Vision, Mission & Values Our Vision • To offer reliable, affordable and effective healthcare solutions to all by recognizing the great potential of biotechnology to effectively diagnose rare, chronic and severe illnesses. Our Mission • To design and develop molecular diagnostics products of superior
Slide 12: Our Journey
1 Our Journey 2 ie) oO 2011-2013 + Founded as a 12) 2014-2016 + Entry into Molecular Lifesciences company Diagnostics with Launch + Initiated R&D in TRUPCR® its i Molecular Diagnostics 6 RUPCR’ of TRUPCR® MDx Kits in Infectious Diseases & 12) oO 2017-2018 + Received FMPCCI 1 Outstanding Achievement
Slide 13: Our Strategic Priorities
Our Strategic Priorities Market Penetration: Portfolio Expansion: We aim to boost sales with current Leveraging our R&D strengths, we customers and channel partners by continuously evolve our portfolio – with expanding the range of products within new assays in qPCR, Lateral flow their existing port
Slide 14: Growth Canvas
Sales in INR Millions Growth Canvas
Slide 15: MDx Business – Financials Highlights – Q1 2025-26
MDx Business – Financials Highlights – Q1 2025-26 1,996.06 1,619.43 1,694.44 1,458.53 Q1 2024-25 Revenue from Operations EBITDA 1,591.51 1,269.61 Q1 2025-26 Rs. In Lakh. 1,438.73 1,132.75 PBT PAT *Other expenses for Qtr ending 30/6/25 includes one time expenses paid to consultants towards fees for M
Slide 16: Business Outlook – MDx (Q1/2025-26)
Business Outlook – MDx (Q1/2025-26) We closed Q1 2025-26 with INR 1,996.06 Lakh (Including COVID Sales of INR 20.51 Lakh) compared to INR 1,694.44 Lakh in Q1 2024-25. This includes consolidated sales from TRUPCR Europe Limited, Manchester for INR 434.14 Lakh. In Q1 2025-26, we did export of INR 430.
Slide 17: Business Outlook – MDx (FY 2025-26 – 3B India)
Business Outlook – MDx (FY 2025-26 – 3B India) Market Overview & Growth Outlook The Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹350–450 Cr. We hold a 12%–15% market share, positioning us among the market leaders. The MDx industry is projecte
Slide 18: Business Outlook – MDx (FY 2025-26 – 3B India)
Business Outlook – MDx (FY 2025-26 – 3B India) The company operates through three primary sales models in India: a) Tender Sales: This accounts for approximately 5%-7% of the total sales and it depends on type of tender, etc. b) Contractual / Reagent Rental Model: In this model, we provide molecular
Slide 19: Our Footprints in India
Our Footprints in India Head Office & Manufacturing Site Corporate Office – Delhi Sales Office - Mumbai Sales & Marketing Team Distributor Network
Slide 20: Our Global Presence
Our Global Presence We have widespread acceptance globally with our presence now in over 70 countries spanning across Europe, Middle East, APAC, LATAM, and North America (including the United States and Canada). Now we are expanding in Africa through strategic partnerships with channel partners.
Slide 21: Business Outlook – International
Business Outlook – International Global Expansion: Appointed new channel partners to strengthen international presence. Territorial Growth: Added customers in existing and new markets across Europe, Africa, and APAC. Regulatory Progress: Completed product registrations in several countries; on
Slide 22: Exports – Past Trend & Near Term Vision
Exports – Past Trend & Near Term Vision Our exports have grown substantially, as shown by the yearly figures above. This year, we project export growth of 20–25%. We now have presence across 70+ countries & 200+ customers. To drive growth, we are entering new territories; where registrations take ti
Slide 23: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site In Q1 FY 2025-26, TRUPCR® Europe Limited (TPE) grew in line with our 20–25% plan as visible from the sales figures below. GBP 309,204 GBP 380,477 Q1 FY 2024-25 Q1 FY 2025-26 Our UK subsidiary has emerged as a key growth driver, gaining strong traction across
Slide 24: TRUPCR Europe – In Events & Conferences – 2024-25
TRUPCR® Europe – In Events & Conferences – 2024-25 TRUPCR® Europe has been participating in international molecular diagnostic conferences and organizing training sessions and seminars for customers to showcase expertise, build relationships within the industry, and educate customers about its produ
Slide 25: TRUPCR Europe – Upcoming Events & Conferences
TRUPCR® Europe – Upcoming Events & Conferences Like 2024-25, TPE will be participating in extensively in the events and conferences. During the events we will be presenting our product portfolio and introduce new assays, highlighting our commitment to innovation and advancing precision diagnostics o
Slide 26: Events & Conferences - International
Events & Conferences - International Our strong international presence is reinforced through active participation in global conferences, where we showcase our products and introduce new verticals. These events are key to engaging stakeholders, building partnerships, and expanding global awareness. O
Slide 27: Events & Conferences – Pune, INDIA
Events & Conferences – Pune, INDIA Our participation in MICROCON Pune 2024 (Nov 21–24) was a great success, with excellent customer feedback validating our products in pathology and microbiology. This strengthens our brand and fosters deeper engagement with key stakeholders.
Slide 28: Events & Conferences – Meerut, INDIA
Events & Conferences – Meerut, INDIA We participated in UP-UK MICROCON 2024, held at LLRM Medical College, Meerut during February 14th & 15th which was a great success as we had , with excellent customer feedback validating our products in pathology and microbiology. This strengthens our brand and f
Slide 29: Workshops - INDIA
Workshops - INDIA Our sales, marketing, and application teams have been collaborating to organize a series of workshops for both existing users of our kits and prospective clients. These workshops aim to provide valuable insights into the usage and benefits of our products, facilitating enhanced und
Slide 30: Upcoming Events & Conferences
Upcoming Events & Conferences We will be participating in several important molecular biology and microbiology conferences in different parts of India during the next few months. These conferences help us promote our latest research, exchange knowledge with experts in the field, and collaborate on c
Slide 31: Acquisition of 100% Stake in Coris Holding SRL, Belgium
Acquisition of 100% Stake in Coris Holding SRL, Belgium Your company–3B along with its UK subsidiary–TPE is pleased to announce that it has entered into a definitive agreement with Avacta Group Plc, London to acquire all the shares of Coris Holding SRL, the parent company of Coris Bioconcept SRL (“C
Slide 32: Acquisition of 100% Stake in Coris Holding SRL, Belgium
Acquisition of 100% Stake in Coris Holding SRL, Belgium Product Portfolio: Coris’ product portfolio comprises in vitro diagnostic test kits for AntiMicrobial Resistance (AMR), respiratory, gastroenteric and blood-borne pathogens (bacteria, viruses and parasites), however, it is primarily focused on
Slide 33: Strategic Relevance - Acquisition of Coris Bioconcept SRL
Strategic Relevance - Acquisition of Coris Bioconcept SRL Acquisition of Coris BioConcept SRL is a strategically thought move that strengthens our position in the IVD segment and our fight against AMR. The product portfolio of Coris complements our existing molecular diagnostics product range. By co
Slide 34: Our Certifications
Our Certifications ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India Over 120 Parameters are CE-IVD marked
Slide 35: What Sets us Apart
What Sets us Apart Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available Large, expansive and highly loyal customer base spread across government & private hospitals and labs in over 70 countries W ell experienced, strong and well retained R&
Slide 36: Our R&D Strengths
Our R&D Strengths Our well retained R&D team of scientific professionals including Ph.Ds. and M.Scs. brings vast experience in molecular diagnostics, assay design, and bioinformatics which reflects a stable, motivated workforce committed to scientific excellence and long-term innovation. This is
Slide 37: Comprehensive Panels for Syndromic Testing
Comprehensive Panels for Syndromic Testing The COVID-19 pandemic has underscored the importance of multiplex PCR TRUPCR® Flu Panel with RSV Detection Kit assays and syndromic diagnostic testing for infectious diseases, highlighting their utility in rapidly diagnosing and managing contagious illnesse
Slide 38: Antimicrobial Resistance – A Silent Pandemic
Antimicrobial Resistance – A Silent Pandemic Antimicrobial resistance (AMR) has become one of the most significant threats to public health worldwide, often referred to as the "silent pandemic" due to its gradual and insidious nature. Image Source: AMR Action Fund • Encouraging judicious use of anti
Slide 39: Solutions by 3B - to combat Antimicrobial Resistance
Solutions by 3B - to combat Antimicrobial Resistance We offer an extensive range of RT-PCR-based and lateral flow assays that demonstrates our proactive approach to addressing the global concern of antimicrobial resistance (AMR). TRUPCR® have both singlex and multiplexing RT-PCR assays for the detec
Slide 40: TRURAPID
Solutions by 3B - to combat Antimicrobial Resistance We are pleased to inform that we have successfully completed the collaborative R&D of the Rapid Tests for Anti- Microbial Resistance (AMR). The below assays have been launched to cater to the AMR segment: TRURAPID® RESIST-5 OKNVI Rapid Test (For
Slide 41: Next-Gen Sequencing (NGS) Vertical
Next-Gen Sequencing (NGS) Vertical We have started getting some traction for the TRUNGS® assays from the customers however, it is very low. The NGS market is at a very nascent stage and is divided in Whole Genome Sequencing, Whole Exome Sequencing, NIPT etc. With the TRUNGS® vertical, our main inten
Slide 42: Digital PCR
Digital PCR Our Research and Development (R&D) team is committed to the ongoing development of innovative products leveraging cutting-edge technologies. Through our dedication to scientific advancement and technological innovation, we strive to address emerging challenges and meet the evolving needs
Slide 43: Automated Extraction System
Automated Extraction System We are trying to offer automated extraction systems to our customers. Our team alongwith VGT’s team has invested considerable time and effort into identifying an automated extraction system that meets the growing needs of our customers. With this new addition, we are conf
Slide 44: Long Term Contracts
Long Term Contracts Signing long-term contracts with large customers is a strategic move that provides stability and predictability to the business operations. By securing commitments for 2-3 years, we can better forecast revenue streams and plan resources accordingly, reducing uncertainty and mitig
Slide 45: Utilization of Funds, Dividend for FY 2024-25, Existing & Utilized Capacity
Utilization of Funds During the last 2 years, we have evaluated several companies in the IVD space, however, the valuations were high due to demand from diagnostic companies based on Covid profits. Also, the Sales & EBITDA were not matching our IRR or future growth possibility, hence we did not proc
Slide 46: 3B for CSR
3B for CSR Army Wives Welfare Association or AWWA for short is an association that works for the welfare of the spouses, children and dependents of Army personnel. The aim of AWWA therefore is to support and augment the official welfare efforts within the Indian Army, focusing primarily on the wel-
Slide 47: 3B for CSR
3B for CSR Sightsavers is an international organisation that works in more than 30 countries to eliminate avoidable blindness, and fight for the rights & needs of people with disability. Sightsavers’ work in India has enabled thousands of people to lead lives of independence and dignity. “3B” has be
Slide 48: 3B for CSR
3B for CSR Prerna Sewa Trust, Bhopal, has been serving poor patients at Hamidia Hospital, Bhopal for decades through daily meals, free medicines, medical equipment, and support for treatment of serious ailments. In line with our CSR commitment, 3B has been supporting the Trust by funding medical aid
Slide 49: Recognitions & Awards
Recognitions & Awards Received the “Outstanding Received the “National Received the “Outstanding Achievement Award” in MSME Award – 2018” by Achievement Award” in recognition of excellence in Hon’ble President of India on recognition of excellence in R&D through technology by 11th May 2018 under MSM
Slide 50: JAI HIND
JAI HIND 2B BlackBio Dx Ltd.